MarketCap
Facebook
X
TelegramAnnual report 2022
added 07-25-2022
Taro Pharmaceutical Industries Ltd. Depreciation & Amortization 2011-2026 | TARO
Annual Depreciation & Amortization Taro Pharmaceutical Industries Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.9 M | 23.7 M | 21.4 M | 18.6 M | 16.5 M | 14.8 M | 14.8 M | 15.8 M | 16.6 M | 17.8 M | - | 18.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.9 M | 14.8 M | 18.6 M |
Quarterly Depreciation & Amortization Taro Pharmaceutical Industries Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.6 M | - | - | - | 4.71 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.71 M | 4.6 M | 4.65 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 327.0 | -1.92 % | $ 42.8 B | USA |
 |
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Cabaletta Bio
CABA
|
1.65 M | $ 3.52 | 3.38 % | $ 354 M | USA |
 |
Aligos Therapeutics
ALGS
|
930 K | $ 8.24 | 11.12 % | $ 81.5 M | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 21.94 | 1.2 % | $ 1.03 B | USA |
 |
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.13 | -3.52 % | $ 5.15 M | Israel |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
154 K | - | -5.16 % | $ 5.39 M | USA |
 |
Galectin Therapeutics
GALT
|
1 K | $ 2.34 | -8.79 % | $ 150 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.4 | -10.0 % | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
548 K | $ 4.22 | -0.59 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.2 | -1.55 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.53 | 2.68 % | $ 407 M |  Britain |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
174 K | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
67 K | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
3.38 M | $ 33.66 | -0.62 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | USA |